Pre-Cure is a next-generation, multifunctional 3D human-lab platform for preclinical oncology drug testing. Its proprietary assays evaluate agents across all eight hallmarks of cancer for any solid tumor type. Built on deep expertise in 3D cell culturing, advanced tissue engineering, microfluidics, and 3D printing, the platform centers on a cutting-edge biomimetic device that mirrors the body’s physiological context and preserves the full complexity of the tumor microenvironment (TME) better than any other platform. Pre-Cure supports all major treatment modalities—including immunotherapy, radiotherapy, chemotherapy, ADCs, and nanoparticles—and pairs its readouts with AI to uncover phenotypic patterns across cancer hallmarks. This enables a deeper understanding of mechanisms of action and improves the prediction of therapeutic response.